AU650569B2 - Imidazol-1-yl methyl pyridine derivatives, processes for their production and their use as pharmaceuticals - Google Patents
Imidazol-1-yl methyl pyridine derivatives, processes for their production and their use as pharmaceuticals Download PDFInfo
- Publication number
- AU650569B2 AU650569B2 AU25226/92A AU2522692A AU650569B2 AU 650569 B2 AU650569 B2 AU 650569B2 AU 25226/92 A AU25226/92 A AU 25226/92A AU 2522692 A AU2522692 A AU 2522692A AU 650569 B2 AU650569 B2 AU 650569B2
- Authority
- AU
- Australia
- Prior art keywords
- compound
- alkyl
- formula
- acid addition
- free base
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Veterinary Medicine (AREA)
- Neurology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Psychiatry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
- Luminescent Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Compounds of the formula I <IMAGE> in which R1 denotes alkyl having 1 to 4 carbon atoms, halogen having an atomic number of 9 to 35 or amino which is optionally mono- or disubstituted by alkyl having 1 to 4 carbon atoms, R2 and R3 independently of one another stand for hydrogen or alkyl having 1 to 4 carbon atoms and R4 denotes hydrogen, hydroxyl, alkyl or alkoxy each having 1 to 4 carbon atoms or halogen having an atomic number of 9 to 35, in the form of the free base or in acid addition salt form, can be used for the treatment of senile dementia and Alzheimer's disease and as antidepressant.
Description
650569
AUSTRALIA
PATENTS ACT 1990 COMPLETE SPECIFICATION NAME OF APPLICANT(S): Sandoz Ltd.
ADDRESS FOR SERVICE: DAVIES COLLISON CAVE Patent Attorneys 1 Little Collins Street, Melbourne, 3000.
INVENTION TITLE: S""Imidazol-1-yl methyl pyridine derivatives, processes for their production and their use as pharmaceuticals".
SThe following statement is a full description of this invention, including the best method of performing it known to me/us:ao la The present invention relates to imidazolylmethyl-pyridines, their production, their use as pharmaceuticals and pharmaceutical compositions containing them.
More particularly the present invention provides compounds of formula I, 3
R
R H R R2 wherein RI is alkyl (1-4 halogen with an atomic number of 9 to 35 or amino optionally mono- or disubstituted by alkyl (1-4 C),
R
2 and R 3 independently of one another are hydrogen or alkyl (1-4 C) and
R
4 is hydrogen, hydroxy, alkyl (1-4 alkoxy (1-4 C) or halogen with an atomic number of 9 to in free base or acid addition salt form, hereinafter refferd to as new compounds.
2 100-7825 Insofar as above-defined alkyl or alkoxy groups are present in the new compounds, these preferably have one or two carbon atoms and especially signify methyl or methoxy.
The imidazolylmethyl radical is preferably in position 2 of the pyridine.
RI is preferably methyl. R 2 and R 3 are preferably each hydrogen. R 4 is preferably hydrogen. The compound of Example 1 is preferred.
In a particular group of new compounds, Ri is alkyl (1-4 R 2 and
R
3 independently of one another are hydrogen or alkyl (1-4 C) and R 4 is hydrogen, alkyl (1-4 C) or halogen with an atomic number of 9 to
S..
In accordance with the invention, the new compounds are obtained by reacting a compound of formula II, x
(II)
R
4 O* wherein R 4 is defined as above, and X is halogen, with a compound of formula III,
R
HN
I)
(III)
wherein R 1
R
2 and R 3 are defined as above, 3 100-7825 and recovering the resulting compound of formula I in free base form or in acid addition salt form.
The reaction of the compound of formula II with the compound of formula II may take place in known manner, in a solvent which is inert under the reaction conditions, e.g. in dimethylformamide or a lower alcohol. In formula II, X is preferably chlorine.
Working up of the reaction mixtures obtained and purification of the compounds of formula I thus produced may take place in accordance with known methods.
The compounds of formula I may be present in free form or in the form of their acid addition salts. Acid addition salts may be produced from the free bases in known manner, and vice versa.
S. The starting compounds of formulae II and III are known or may be produced in accordance with known processes, resp. analogously to known processes.
The compounds of formula I and their physiologically acceptable salts, hereinafter referred to as compounds according to the invention, exhibit interesting pharmacological activities and may therefore be used as pharmaceuticals.
In the sleep/wake cycle of the long-term implanted rat [for the method, see Vigouret et al., J. Pharmacol 10, 503 (1978)], the compounds according to the invention when administered at 1 to 100 mg/kg p.o. effect an increase in vigilance by prolonging the wake phases.
4 100-7825 Moreover after administration of 1 to 100 mg/kg p.o. to rats with bilateral lesions of the Locus coeruleus (LC) and the Nucleus basalis Meynert (NBM), the compounds according to the invention improve significantly the cognitive performance as measured by the ability to avoid an electric shock in the shuttle box.
The method is similar to that described by V. Haroutunian et al. in Brain Research 507 (1990) 261 266. Male OFA rats (300 g) are anaesthetized with pentobarbital and positioned in a stereotaxic apparatus with the upper incisor bar set 5 mm (LC) or 3.3 mm (NBM) below the interaural line. The lesions are carried out with a radio frequency lesion generator at 60 o C during 10 seconds. 5 weeks after lesioning, behavioral testing is performed, using the active avoidance test in the shuttle box as described by A.R. Dravid, Jaton and E.B. Van Deusen in Experimental Brain Research, Suppl. 13, p. 249 (1986).
The compounds according to the invention are therefore useful for the treatment of senile dementia, Alzheimer's disease and further degenerative diseases such as Huntington's chorea, Morbus Parkinson, Steel-Richardson syndrome, tazdive dyskinesias, hyperkinesia, acute confusion disorders, Down's syndrome, myasthenia gravis and Friedrich's ataxia, furthermore as antidepressants.
An indicated daily dosage is in the range from about 1 mg to about 100 mg of a compound according to the invention, conveniently administered, for example, in divided doses up to four times a day.
The compounds according to the invention may be administered by any conventional route, in particular enterally, preferably orally, for example in the form of tablets or capsules, or parenterally, for example in the form of injectable solutions or suspensions.
5 100-7825 In accordance with the foregoing, the present invention also provides a compound according to the invention, for use as a pharmaceutical, e.g. for the treatment of 6enile dementia, Alzheimer's disease and further degenerative diseases such as Huntington's chorea, Morbus Parkinson, Steel-Richardson syndrome, tardive dyskinesias, hyperkinesia, acute confusion disorders, Down's syndrome, myasthenia gravis and Friedrich's ataxia, and for the treatment of depression.
The present invention furthermore provides a pharmaceutical composition comprising a compound according to the invention in association with at least one pharmaceutical carrier or diluent. Such compositions may be manufactured in conventional manner. Unit dosage forms contain, for example, from about 0.25 mg to about 50 mg of a compound according to this invention.
The following examples illustrate the invention. The temperatures are given in degrees Celsius and are uncorrected.
S.
S*
•g 6 100-7825 EXAMPLE 1: [2-(2-methylimidazol-l-yl)methyl]pyridine 9.7 g (75 mM) of 2-(chloromethyl)pyridine and 42 g (512 mM) of 2-methyl-imidazole are suspended in 40 ml dimethylformamide, then stirred for 3 hours at 105 0. The dimethylformamide is distilled off and the crystalline residue is diluted with ethyl acetate and a little hexane. Following filtration, the mother solution is concentrated by evaporation and the dimethylformamide distilled off, and then shaken out several times between water and methylene chloride. 10.3 g of the oily title compound are obtained.
9.3 g of the obtained base in ethanol are mixed with 12.7 g of fumaric acid. The resulting bis(base)-tris(hydrogen fumarate)crystallizes from ethanol/ethyl acetate and is recrystallized once from ethanol/ethyl acetate. It is uniform upon thin-layer chromatography and melts at 109 110 o The following [2-(imidazol-l-yl)methyl]pyridines are produced analogously to example 1: *e Example R 1
R
2
R
3
R
4 M.p.
2 CH3 H H 6-CH3 129 130 a 3 CH3 CH 3 H H 250 253 0 (decomp.) 4 CH3 H CH3 H 213 220 O (decomp.) fumarate dihydrochloride 7 100-7825 as well as the following [4-(imidazol-1-yl)methyljpyridine: Example R, R 2
R
3
R
4
M.P.
CH
3 H H H 155 56 0 fumarate of* 0 00 000.
7a Throughout this specification and the claims which follow, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising", will be underst~od to imply the inclusion of a stated integer or group of integers but not the exclusion of any other integer or group of integers.
S.
SS
S.
S
S. S S S
S.
S
S.
S S S
S
55 S S S
S.
S
5555 S S
S*
S..
*S S
SS
S *S
S
94G427,q:\opcr\dab,25226xMs7
Claims (1)
100-7825 e r r r r o o THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS: 1. A process for the production of a compound of formula I, RN N (I) 3 R 2 wherein RI is alkyl (1-4 halogen with an atomic number of 9 to 35 or amino optionally mono- or disubstituted by alkyl (1-4 C), R 2 and R 3 independently of one another are hydrogen or alkyl (1-4 C) and R 4 is hydrogen, hydroxy, alkyl (1-4 alkoxy (1-4 C) or halogen with an atomic number of 9 to in free base or acid addition salt form, which includes the step of reacting a compound of formula II, I '(II) R 4 wherein R 4 is defined as above, and X is halogen, with a compound of formula III, *Q r a I 9 100-7825 R HN N H (III) R 3 R wherein R 1 R 2 and R 3 are defined as above, and recovering the resulting compound of formula I in free base form or in acid addition salt form. 2. A process for the production of a compound of formula I in free base form or in acid addition salt form, substantially as hereinbefore described with reference to the examples. 3. A compound of formula I in free base form or acid addition salt form, whenever produced by the process of claim 1. 4. A compound of formula I in free base form or acid addition salt e* form, as defined in claim 1. 5. A compound of claim 4 wherein RI is alkyl (1-4 R 2 and R 3 independently of one another are hydrogen or alkyl (1-4 C) and R 4 is hydrogen, alkyl (1-4 C) or halogen with an atomic number of 9 to 35, in free base or acid addition salt form. 9 9 6. A compound of claim 4 which is the [2-(2-methyliaidazol- l-yl)methyl]pyridine, in free base or acid addition salt form. 10 100-7825 7. A compound of claim 4 wherein RI CH3, R 2 H, R 3 H 6-CH 3 or RI CH3, R 2 CH3, R 3 H, R 4 H, or R 1 CH 3 R 2 H, R 3 CH 3 R 4 H, and the imidazolylmethyl group is in position 2, or RI CH 3 R 2 H, R 3 H, R 4 H and the imidazolylmethyl group is in position 4, in free base or acid addition salt form. 8. A compound of any one of claims 3 to 7 in physiologically acceptable form, for use as a pharmaceutical. 99 9. A compound of any one of claims 3 to 7 in physiologically acceptable form, for use in the treatment of senile dementia, Alzheimer's disease, Huntington's chorea, Morbus Parkinson, Steel-Richardson syndrome, tardive dyskinesia, hyperkinesia, acute confusion disorders, Down's syndrome, myasthenia gravis or Friedrich's ataxia, or in the treatment of depression. A pharmaceutical composition comprising a compound according to S* any one of claims 3 to 7 in physiologically acceptable form, in association with a pharmaceutical carrier or diluent. indicated in the specification and/or cas is application, individually or colles n any and all combinations or any DATED this TWENTY FIRST day of SEPTEMBER 1992 Sandoz Ltd. by DAVIES COLLISON CAVE Ay Patent Attorneys for the applicant(s) Abstract of the disclosure Compounds of formula I, S. C 8A AAA A wherein R, to R 4 possess the significances given in the description, may be used in the treatment of senile dementia, Alzheimer's disease and depression. AS A. A. S A. A 6300/VY/ER
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE4131584A DE4131584A1 (en) | 1991-09-23 | 1991-09-23 | IMIDAZOLYLMETHYL-PYRIDINE, THEIR PRODUCTION AND USE AS A PHARMACEUTICAL |
| DE4131584 | 1991-09-23 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2522692A AU2522692A (en) | 1993-03-25 |
| AU650569B2 true AU650569B2 (en) | 1994-06-23 |
Family
ID=6441240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU25226/92A Ceased AU650569B2 (en) | 1991-09-23 | 1992-09-21 | Imidazol-1-yl methyl pyridine derivatives, processes for their production and their use as pharmaceuticals |
Country Status (24)
| Country | Link |
|---|---|
| EP (1) | EP0534904B1 (en) |
| JP (1) | JP2568356B2 (en) |
| KR (1) | KR100254085B1 (en) |
| AT (1) | ATE144509T1 (en) |
| AU (1) | AU650569B2 (en) |
| CA (1) | CA2078700C (en) |
| CZ (1) | CZ281675B6 (en) |
| DE (2) | DE4131584A1 (en) |
| DK (1) | DK0534904T3 (en) |
| ES (1) | ES2092666T3 (en) |
| FI (1) | FI103887B (en) |
| GR (1) | GR3021444T3 (en) |
| HU (2) | HUT61993A (en) |
| IL (1) | IL103229A (en) |
| MX (1) | MX9205365A (en) |
| MY (1) | MY110450A (en) |
| NO (1) | NO301162B1 (en) |
| NZ (1) | NZ244420A (en) |
| RO (1) | RO109337B1 (en) |
| RU (1) | RU2058312C1 (en) |
| SG (1) | SG43079A1 (en) |
| SK (1) | SK289692A3 (en) |
| TW (1) | TW222630B (en) |
| ZA (1) | ZA927279B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10165349A (en) * | 1996-12-06 | 1998-06-23 | Matsushita Electric Ind Co Ltd | Dish washer |
| DE10000161A1 (en) * | 2000-01-06 | 2001-07-19 | Boehringer Ingelheim Pharma | Determining test substances that inhibit protease, involves incubating cells expressing fusion protein having substrate with cleavage site for protease and reporter, measuring cleaved reporter and comparing with standard |
| GB0009037D0 (en) * | 2000-04-13 | 2000-05-31 | Novartis Ag | Organic compounds |
| NZ565763A (en) * | 2005-07-29 | 2010-12-24 | Vanda Pharmaceuticals Inc | Method of improving wakefulness |
| JP5044572B2 (en) * | 2006-02-13 | 2012-10-10 | ヴァンダ ファーマシューティカルズ インコーポレイテッド | Stable dosage formulation of imidazolylalkyl-pyridine |
| WO2009097416A1 (en) * | 2008-01-29 | 2009-08-06 | Vanda Pharmaceuticals, Inc. | Imidazolylalkyl- pyridines as dbh inhibitors |
| KR20110071014A (en) | 2008-10-17 | 2011-06-27 | 위스콘신 얼럼나이 리서어치 화운데이션 | Method of making biologically active alpha-beta peptides |
| US9394290B2 (en) * | 2010-10-21 | 2016-07-19 | Universitaet Des Saarlandes Campus Saarbruecken | Selective CYP11B1 inhibitors for the treatment of cortisol dependent diseases |
| JP2020520952A (en) * | 2017-05-22 | 2020-07-16 | トーリー パインズ インスティテュート フォー モレキュラー スタディーズＴｏｒｒｅｙ Ｐｉｎｅｓ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｍｏｌｅｃｕｌａｒ Ｓｔｕｄｉｅｓ | Compositions, methods of use and methods of treatment |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2862340D1 (en) * | 1978-02-01 | 1983-11-24 | Wellcome Found | Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations thereof |
| GB2028317B (en) * | 1978-08-15 | 1982-11-10 | Pfizer Ltd | 2-(imidazol-1-ylmethyl)-pyridine and -quinoline thromboxane synthetase inhibitors |
| US4634711A (en) * | 1985-08-02 | 1987-01-06 | Smithkline Beckman Corporation | Pyridylalkyl imidazole-2-thiols |
| DE3811574A1 (en) * | 1988-03-31 | 1989-10-19 | Schering Ag | N-SUBSTITUTED IMIDAZOLES, METHODS FOR THEIR PRODUCTION AND THEIR USE IN MEDICINAL PRODUCTS |
-
1991
- 1991-09-23 DE DE4131584A patent/DE4131584A1/en not_active Withdrawn
-
1992
- 1992-09-09 HU HU9202886A patent/HUT61993A/en unknown
- 1992-09-18 MY MYPI92001673A patent/MY110450A/en unknown
- 1992-09-21 AU AU25226/92A patent/AU650569B2/en not_active Ceased
- 1992-09-21 IL IL10322992A patent/IL103229A/en not_active IP Right Cessation
- 1992-09-21 FI FI924233A patent/FI103887B/en not_active IP Right Cessation
- 1992-09-21 AT AT92810719T patent/ATE144509T1/en active
- 1992-09-21 NZ NZ244420A patent/NZ244420A/en not_active IP Right Cessation
- 1992-09-21 NO NO923653A patent/NO301162B1/en not_active IP Right Cessation
- 1992-09-21 SG SG1996003366A patent/SG43079A1/en unknown
- 1992-09-21 EP EP92810719A patent/EP0534904B1/en not_active Expired - Lifetime
- 1992-09-21 DK DK92810719.2T patent/DK0534904T3/en active
- 1992-09-21 CZ CS922896A patent/CZ281675B6/en not_active IP Right Cessation
- 1992-09-21 CA CA002078700A patent/CA2078700C/en not_active Expired - Fee Related
- 1992-09-21 SK SK2896-92A patent/SK289692A3/en not_active IP Right Cessation
- 1992-09-21 DE DE59207425T patent/DE59207425D1/en not_active Expired - Lifetime
- 1992-09-21 ES ES92810719T patent/ES2092666T3/en not_active Expired - Lifetime
- 1992-09-22 KR KR1019920017228A patent/KR100254085B1/en not_active IP Right Cessation
- 1992-09-22 MX MX9205365A patent/MX9205365A/en unknown
- 1992-09-22 RO RO92-01218A patent/RO109337B1/en unknown
- 1992-09-22 RU SU925052552A patent/RU2058312C1/en active
- 1992-09-22 JP JP4252692A patent/JP2568356B2/en not_active Expired - Fee Related
- 1992-09-23 ZA ZA927279A patent/ZA927279B/en unknown
- 1992-09-24 TW TW081107550A patent/TW222630B/zh active
-
1995
- 1995-06-13 HU HU95P/P00198P patent/HU211261A9/en unknown
-
1996
- 1996-10-24 GR GR960402593T patent/GR3021444T3/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI87785C (en) | FREQUENCY REQUIREMENT FOR PHARMACEUTICAL ACTIVATION, CRYSTALLINE PAROXETYHYDROCHLORIDE HEMIHYDRATE | |
| AT405283B (en) | NEW CRYSTALLINE 7- (Z) - (2- (2-AMINOTHIAZOL-4-YL) -2-HYDROXYIMINOACETAMIDO) -3-VINYL-3-CEPHEM-4- CARBONIC ACID DICYCLOHEXYLAMMONIUM SALTS AND METHODS FOR THE PRODUCTION THEREOF | |
| EP2155696B1 (en) | Piperazine salts as d3/d2 antagonists | |
| WO2007129111A1 (en) | Diazepine derivatives as 5-ht2a antagonists | |
| AU650569B2 (en) | Imidazol-1-yl methyl pyridine derivatives, processes for their production and their use as pharmaceuticals | |
| US4797489A (en) | Adamantyl- and fluorenyl-arylpiperazines and -arylpiperidines | |
| EP0309544B1 (en) | Psychotropic bicyclic imides | |
| DE69217308T2 (en) | Dihydropyridines for use in antitumor therapy | |
| EP4001276A1 (en) | Aurora kinase inhibitor and use thereof | |
| JP2022547390A (en) | VMAT2 inhibitor, its preparation method, and its use | |
| DD286581A5 (en) | PROCESS FOR THE PREPARATION OF HETERA-ALIPHATIC CARBONIC ACID AMIDES | |
| DE68910451T2 (en) | 1,4-BENZOXAZINE AND 1,4-BENZOTHIAZINE DERIVATIVES AND METHOD FOR THE PRODUCTION THEREOF. | |
| NO172490B (en) | ANALOGY PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE 1,4-DISUBSTITUTED PIPERAZINE DERIVATIVES | |
| MXPA05009129A (en) | Process for producing acid adduct salt of polyacidic base compound. | |
| US5635521A (en) | Imidazolylmethyl-pyridines | |
| DE69702419T2 (en) | Substituted guanidine derivatives and their use as Na + / H + exchange inhibitors | |
| AU621408B2 (en) | Phenylalkyl or phenylalkoxyethyl substituted piperazine derivatives | |
| EP0737677A1 (en) | 4-Indolylpiperazinyl derivates | |
| US5958945A (en) | Naphthamide derivatives of 3-beta-amino azabicyclo octane or nonane as neuroleptic agents | |
| EP0964865A2 (en) | Pharmaceutically active tricyclic amines | |
| DE1720033A1 (en) | New indole derivatives and processes for their preparation | |
| CS240970B2 (en) | Process for preparating substituted phenylalkylamides ofphenylacetic acid | |
| HU187600B (en) | Process for preparing 2-methyl-9,10-didehydro-ergolines | |
| EP2121643B1 (en) | New process for the preparation of levocetirizine and intermediates thereof | |
| JPH10505853A (en) | Bicyclic carboxamides as 5-HT1A antagonists |